| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 367 | 2020 |
| A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1–positive, regulatory, cytotoxic, and helper T cells and macrophages BE Wahlin, M Aggarwal, S Montes-Moreno, LF Gonzalez, G Roncador, ... Clinical Cancer Research 16 (2), 637-650, 2010 | 210 | 2010 |
| CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma BE Wahlin, B Sander, B Christensson, E Kimby Clinical Cancer Research 13 (2), 388-397, 2007 | 192 | 2007 |
| Clinical significance of the WHO grades of follicular lymphoma in a population‐based cohort of 505 patients with long follow‐up times BE Wahlin, OE Yri, E Kimby, H Holte, J Delabie, EB Smeland, ... British journal of haematology 156 (2), 225-233, 2012 | 190 | 2012 |
| Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML AT Björklund, M Carlsten, E Sohlberg, LL Liu, T Clancy, M Karimi, ... Clinical Cancer Research 24 (8), 1834-1844, 2018 | 180 | 2018 |
| Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study HR Junlén, S Peterson, E Kimby, S Lockmer, O Lindén, H Nilsson-Ehle, ... Leukemia 29 (3), 668-676, 2015 | 144 | 2015 |
| The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era YN Blaker, S Spetalen, M Brodtkorb, OC Lingjærde, K Beiske, ... British journal of haematology 175 (1), 102-114, 2016 | 74 | 2016 |
| The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium B Sander, D de Jong, A Rosenwald, W Xie, O Balagué, M Calaminici, ... haematologica 99 (4), 715, 2014 | 70 | 2014 |
| M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy S Lockmer, W Ren, M Brodtkorb, B Østenstad, BE Wahlin, ... British journal of haematology 188 (2), 259-267, 2020 | 62 | 2020 |
| Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy E Zucca, S Rondeau, A Vanazzi, B Østenstad, UJM Mey, D Rauch, ... Blood, The Journal of the American Society of Hematology 134 (4), 353-362, 2019 | 60 | 2019 |
| Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two nordic lymphoma group trials with more than 10 years of … S Lockmer, B Østenstad, H Hagberg, H Holte, AS Johansson, BE Wahlin, ... J Clin Oncol 36 (33), 3315-3323, 2018 | 60 | 2018 |
| T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab BE Wahlin, C Sundström, H Holte, H Hagberg, M Erlanson, ... Clinical Cancer Research 17 (12), 4136-4144, 2011 | 55 | 2011 |
| Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden S Harrysson, S Eloranta, S Ekberg, G Enblad, M Jerkeman, BE Wahlin, ... Blood cancer journal 11 (1), 9, 2021 | 49 | 2021 |
| Entourage: the immune microenvironment following follicular lymphoma BE Wahlin, B Sander, B Christensson, B Østenstad, H Holte, PD Brown, ... Blood cancer journal 2 (1), e52-e52, 2012 | 47 | 2012 |
| T-cell levels are prognostic in mantle cell lymphoma L Nygren, AM Wasik, S Baumgartner-Wennerholm, Å Jeppsson-Ahlberg, ... Clinical Cancer Research 20 (23), 6096-6104, 2014 | 45 | 2014 |
| Targeting the immune microenvironment in lymphomas of B-cell origin: from biology to clinical application TA Mulder, BE Wahlin, A Österborg, M Palma Cancers 11 (7), 915, 2019 | 31 | 2019 |
| Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas E Kimby, B Östenstad, P Brown, H Hagberg, M Erlanson, H Holte, ... Leukemia & lymphoma 56 (9), 2598-2607, 2015 | 31 | 2015 |
| Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma S Ekberg, M Jerkeman, PO Andersson, G Enblad, BE Wahlin, ... American Journal of Hematology 93 (8), 1020-1028, 2018 | 28 | 2018 |
| Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study T Wästerlid, JL Biccler, PN Brown, M Bøgsted, G Enblad, JM Jørgensen, ... Annals of Oncology 29 (8), 1882-1883, 2018 | 27 | 2018 |
| Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy BE Wahlin, C Sundström, B Sander, B Christensson, Å Jeppsson-Ahlberg, ... Leukemia & Lymphoma 55 (2), 288-295, 2014 | 27 | 2014 |
